LONDON - 4basebio PLC (AIM: 4BB), a biotechnology firm specializing in the production of synthetic DNA and nanoparticle delivery systems, disclosed that its CEO, Dr. Heikki Lanckriet, has increased his stake in the company through the acquisition of additional shares. The transaction, which took place on the London Stock Exchange (LON:LSEG)'s AIM market, involved the purchase of 12,000 ordinary shares at a price of 1,315 pence per share.
Following this market purchase, Dr. Lanckriet's total holding in 4basebio now amounts to 1,115,288 shares, representing 7.27% of the company's issued share capital. The company's issued share capital consists of 15,477,395 ordinary shares.
The acquisition by the CEO is considered inside information under EU Market Abuse Regulation, as amended by the UK's market abuse (amendment) (EU Exit) regulations. This regulatory framework ensures transparency in financial transactions by company insiders, providing investors with key information regarding the actions of company executives.
4basebio's focus is on the advancement of advanced therapy medicinal products (ATMPs) by supplying high-quality synthetic DNA for research, therapeutic, and pharmacological use, as well as developing targeted non-viral vectors for efficient payload delivery in patients. The company aims to become a market leader in its field.
The notification of the transaction is in compliance with Article 19(1) of Regulation (EU) No. 596/2014, which mandates public disclosure of transactions conducted by persons discharging managerial responsibilities within an issuer.
Investors often monitor insider transactions as they can provide insights into executives' confidence in the company's prospects. Dr. Lanckriet's purchase may be interpreted as a positive signal regarding 4basebio's future.
This report is based on a press release statement from 4basebio PLC.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.